Equities

Gland Pharma Ltd

Gland Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,755.05
  • Today's Change-30.45 / -1.71%
  • Shares traded101.15k
  • 1 Year change+2.02%
  • Beta0.6336
Data delayed at least 15 minutes, as of Nov 22 2024 10:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.

  • Revenue in INR (TTM)58.90bn
  • Net income in INR6.92bn
  • Incorporated1978
  • Employees4.22k
  • Location
    Gland Pharma LtdSurvey No.143-148,150&151Near Gandimaisamma 'X' RoadsD.P Pally, Dundigal Gandimaisamma MandaHYDERABAD 500043IndiaIND
  • Phone+91 4 030510999
  • Fax+91 4 030510800
  • Websitehttps://glandpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eris Lifesciences Ltd24.98bn3.48bn186.04bn3.08k53.456.7129.877.4525.5725.57183.35203.740.45852.905.968,110,753.006.7313.428.3916.8077.0379.9814.6924.960.85993.410.4626--19.2315.392.576.1527.72--
Neuland Laboratories Ltd.15.28bn2.80bn189.47bn1.65k67.7513.6555.1412.40217.98217.981,191.201,081.520.8472.144.859,273,565.0015.509.2520.0312.7152.1447.8118.3011.991.4031.560.07287.1330.8418.5183.5178.7617.8863.45
Wockhardt Ltd29.49bn-2.88bn190.86bn2.39k--5.31--6.47-19.85-19.85201.29221.320.3931.874.1912,318,300.00-3.93-4.56-6.33-8.2959.1055.26-10.00-12.700.56770.2470.3869--5.55-4.7317.17---4.71--
Alembic Pharmaceuticals Ltd63.57bn6.47bn204.00bn14.86k31.564.1722.063.2132.8832.88323.14248.680.9290.93665.434,278,678.009.4510.7213.3214.2573.8465.9810.1712.470.805712.620.179128.2910.199.6280.071.05-15.5914.87
Concord Biotech Ltd10.86bn3.28bn208.31bn1.38k53.7613.1054.5819.1937.0437.04114.79152.020.6551.113.557,884,886.0019.78--21.82--76.00--30.20--4.83194.730.0022--19.20--28.33------
Pfizer Ltd22.38bn6.18bn234.75bn1.72k37.996.2634.5810.49135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Emcure Pharmaceuticals Ltd72.56bn5.67bn242.76bn11.15k42.275.8925.283.3530.3730.37389.63217.790.9781.803.966,510,068.008.027.1413.5513.9361.1159.298.207.810.95495.250.21650.0011.237.14-6.3621.35-5.93--
Natco Pharma Ltd.45.61bn19.45bn246.23bn4.02k12.663.4411.545.40108.58108.58254.65399.190.62910.89283.5711,356,080.0026.8212.3330.8514.2585.4773.0542.6325.164.19108.700.028318.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn263.73bn6.01k201.066.3848.375.222.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
J B Chemicals and Pharmaceuticals Ltd37.11bn6.11bn264.35bn5.31k44.278.2334.407.1238.4538.45233.33206.820.94812.594.856,987,882.0015.6115.7718.6218.8966.2661.1816.4716.062.2027.530.030333.0810.6316.2234.8423.3640.1537.42
Gland Pharma Ltd58.90bn6.92bn294.41bn4.22k42.573.3527.385.0041.9841.98357.57533.410.55671.284.1113,967,630.006.5413.237.6514.5660.3055.5811.7422.923.1433.110.03587.2656.2922.61-1.1011.3224.02--
Suven Pharmaceuticals Ltd9.61bn2.43bn324.43bn1.05k133.6416.40106.9333.759.549.5437.7377.710.41561.525.999,136,501.0010.5023.1711.5026.2061.4258.8525.2733.214.0029.500.019118.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m324.55bn6.72k721.714.1040.343.730.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Ajanta Pharma Ltd44.91bn8.75bn367.93bn7.84k42.3510.0136.368.1969.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd85.33bn6.61bn399.22bn17.34k60.375.9637.424.6826.0726.07336.37264.100.74831.124.784,922,642.005.8810.339.0013.5267.3659.167.8512.251.3225.330.12912.8623.3915.3516.134.2417.9021.67
GlaxoSmithKline Pharmaceuticals Limited35.60bn6.75bn401.43bn3.21k59.8424.0053.9911.2739.6039.60209.3198.741.012.5914.8511,088,370.0019.2411.0136.0917.8861.7055.7718.9612.251.38554.800.0088192.076.212.00-2.915.78-36.029.86
Data as of Nov 22 2024. Currency figures normalised to Gland Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

32.03%Per cent of shares held by top holders
HolderShares% Held
Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Oct 202412.74m7.73%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 202410.29m6.24%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 20249.17m5.57%
ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 20246.96m4.23%
SBI Funds Management Ltd.as of 31 Oct 20244.92m2.99%
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 20242.15m1.30%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 20242.06m1.25%
Goldman Sachs Asset Management LPas of 08 Nov 20241.97m1.20%
Norges Bank Investment Managementas of 30 Jun 20241.42m0.86%
DSP Asset Managers Pvt. Ltd.as of 31 Oct 20241.07m0.65%
More ▼
Data from 30 Jun 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.